Soligenix Receives EMA Orphan Drug Designation for SGX945
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy SNGX?
Soligenix announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has granted orphan drug designation to dusquetide, the active pharmaceutical ingredient in SGX945, for the treatment of Behcet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behcet's Disease. SGX945 has previously been granted both orphan drug and fast track designations from the FDA for the treatment of Behcet's Disease. Orphan drug designation by the EMA provides a 10-year period of marketing exclusivity in the EU after product approval. Orphan designation also provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNGX
Wall Street analysts forecast SNGX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.421
Low
10.00
Averages
10.00
High
10.00
Current: 0.421
Low
10.00
Averages
10.00
High
10.00
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soligenix's FLASH2 Trial Halted Due to Futility, Future Uncertain
- Trial Results Disappoint: Soligenix's FLASH2 trial was halted for futility, as HyBryte™ failed to replicate the significant efficacy seen in the first trial, potentially impacting the company's future R&D direction and investor confidence.
- Cash Position Strained: With approximately $5.9 million in cash, the company faces financial pressure and must evaluate various strategic options, including mergers and acquisitions, to ensure ongoing operations and development capabilities.
- Regulatory Communication Plans: Soligenix intends to engage with the EMA and FDA to discuss potential benefits of HyBryte™ for specific patient subsets, despite the current trial results falling short of expectations, aiming to uncover new development opportunities.
- Market Outlook Uncertain: The halt of the FLASH2 trial casts doubt on HyBryte™'s market approval prospects, potentially necessitating additional clinical trials to meet regulatory requirements, thereby increasing the company's future risks.
See More
Lucid, Soligenix, and Sportradar Shares Under Pressure Amid Setbacks
- LCID Decline Continues: Lucid Group's shares fell 1% on Tuesday, marking its fifth consecutive day of losses due to production scale challenges and persistent operating losses, with first-quarter revenue projected at $280-$284 million and an operating loss of $1 billion, raising concerns about EV demand.
- SNGX Trial Setback: Soligenix's stock plummeted 70% after an independent panel recommended halting its late-stage HyBryte trial for cutaneous T-cell lymphoma, with CEO indicating a review of the full dataset and potential engagement with the FDA and EMA, while holding $5.9 million in cash.
- SRAD Earnings Pressure: Sportradar reported a Q1 loss per share of €0.02 despite revenue growth from €311.2 million to €346.5 million, reiterating its full-year revenue outlook of €1.56-1.58 billion, indicating ongoing profitability challenges.
- Positive Investor Sentiment: Despite reaching fresh 52-week lows, retail sentiment for LCID, SNGX, and SRAD remains broadly positive on Stocktwits, with LCID marked as “extremely bullish” and SNGX and SRAD as “bullish,” reflecting expectations for future rebounds.
See More
Soligenix Faces Major Setback in Clinical Trial
- Trial Setback: Soligenix's HyBryte treatment for cutaneous T-cell lymphoma faced a significant setback as an independent committee recommended halting the Phase 3 FLASH2 trial due to lack of effectiveness, resulting in a more than 70% stock price drop, marking the largest intraday loss in over 14 years.
- Data Review: Despite HyBryte showing statistically significant reductions in CTCL lesions after 6 weeks in the first FLASH study, a similar effect was not observed after 18 weeks in this trial, prompting management to conduct a comprehensive data review to understand the shortfall.
- Orphan Drug Status: Soligenix's Dusquetide received orphan drug designation from the European Commission for treating Behçet's Disease, which could provide up to 10 years of market exclusivity if approved, highlighting the company's strategic positioning in the rare disease sector.
- Strategic Options: With approximately $5.9 million in cash, the company plans to evaluate all strategic options moving forward, including potential mergers and acquisitions, while advancing Dusquetide's development to address the challenges posed by the trial failure.
See More
Soligenix Halts HyBryte Clinical Trial Due to Futility
- Trial Results Disappoint: Soligenix announced the pivotal Phase 3 FLASH2 trial of HyBryte™ for cutaneous T-cell lymphoma was recommended to halt due to interim analysis indicating futility, posing significant R&D challenges for the company.
- Cash Position Strained: With approximately $5.9 million in cash, the company must evaluate all strategic options, including merger and acquisition opportunities, to ensure future liquidity and R&D capabilities.
- Efficacy Discrepancies: Despite demonstrating significant efficacy in the first phase trial, HyBryte™ failed to replicate these results in the 18-week FLASH2 trial, indicating uncertainty in the therapy's effectiveness across different patient populations.
- Regulatory Communication Plans: Soligenix intends to communicate with the EMA and FDA regarding the future development of HyBryte™ after further data analysis, reflecting the company's ongoing commitment to exploring the product's potential.
See More
HyBryte™ Shows Promising Results in Treating Cutaneous T-Cell Lymphoma
- Significant Treatment Success: In a 12-week comparative study, 60% of HyBryte™ patients achieved the defined treatment success level (≥50% improvement in mCAILS score), compared to only 20% for Valchlor®, indicating HyBryte™'s potential in treating cutaneous T-cell lymphoma.
- Superior Safety Profile: HyBryte™ was well tolerated in all patients, while 60% of Valchlor® patients experienced treatment-related adverse events, including rashes and allergic reactions, suggesting that HyBryte™ may be a safer treatment option.
- Sustained Efficacy: In the second open-label treatment cycle, 40% of patients receiving 12 weeks of HyBryte™ treatment demonstrated significant treatment response, with results showing a marked improvement compared to the placebo group, indicating that prolonged treatment can enhance patient outcomes.
- Future Research Prospects: The FDA and EMA have mandated a second successful Phase 3 trial for marketing approval, and the follow-up study FLASH2 has successfully achieved its first safety review milestone, which is expected to accelerate the commercialization process for HyBryte™.
See More
Soligenix Reports FY EPS of -$2.14, Beats Estimates
- Fiscal Year Performance: Soligenix reported a FY GAAP EPS of -$2.14, beating market expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Historical Financial Data: Historical data shows that Soligenix's financial performance has fluctuated over the years; although the current EPS remains negative, the better-than-expected result could lay the groundwork for future profitability.
- Market Reaction Analysis: Investors reacted positively to Soligenix's earnings report, which may drive the stock price up in the short term, reflecting market optimism regarding the company's future prospects.
- Quant Rating Attention: Seeking Alpha's Quant Rating on Soligenix highlights market interest in its financial health, prompting investors to closely monitor upcoming financial reports and market developments.
See More
Soligenix's FLASH2 Trial Halted Due to Futility, Future Uncertain
- Trial Results Disappoint: Soligenix's FLASH2 trial was halted for futility, as HyBryte™ failed to replicate the significant efficacy seen in the first trial, potentially impacting the company's future R&D direction and investor confidence.
- Cash Position Strained: With approximately $5.9 million in cash, the company faces financial pressure and must evaluate various strategic options, including mergers and acquisitions, to ensure ongoing operations and development capabilities.
- Regulatory Communication Plans: Soligenix intends to engage with the EMA and FDA to discuss potential benefits of HyBryte™ for specific patient subsets, despite the current trial results falling short of expectations, aiming to uncover new development opportunities.
- Market Outlook Uncertain: The halt of the FLASH2 trial casts doubt on HyBryte™'s market approval prospects, potentially necessitating additional clinical trials to meet regulatory requirements, thereby increasing the company's future risks.
See More
Lucid, Soligenix, and Sportradar Shares Under Pressure Amid Setbacks
- LCID Decline Continues: Lucid Group's shares fell 1% on Tuesday, marking its fifth consecutive day of losses due to production scale challenges and persistent operating losses, with first-quarter revenue projected at $280-$284 million and an operating loss of $1 billion, raising concerns about EV demand.
- SNGX Trial Setback: Soligenix's stock plummeted 70% after an independent panel recommended halting its late-stage HyBryte trial for cutaneous T-cell lymphoma, with CEO indicating a review of the full dataset and potential engagement with the FDA and EMA, while holding $5.9 million in cash.
- SRAD Earnings Pressure: Sportradar reported a Q1 loss per share of €0.02 despite revenue growth from €311.2 million to €346.5 million, reiterating its full-year revenue outlook of €1.56-1.58 billion, indicating ongoing profitability challenges.
- Positive Investor Sentiment: Despite reaching fresh 52-week lows, retail sentiment for LCID, SNGX, and SRAD remains broadly positive on Stocktwits, with LCID marked as “extremely bullish” and SNGX and SRAD as “bullish,” reflecting expectations for future rebounds.
See More
Soligenix Faces Major Setback in Clinical Trial
- Trial Setback: Soligenix's HyBryte treatment for cutaneous T-cell lymphoma faced a significant setback as an independent committee recommended halting the Phase 3 FLASH2 trial due to lack of effectiveness, resulting in a more than 70% stock price drop, marking the largest intraday loss in over 14 years.
- Data Review: Despite HyBryte showing statistically significant reductions in CTCL lesions after 6 weeks in the first FLASH study, a similar effect was not observed after 18 weeks in this trial, prompting management to conduct a comprehensive data review to understand the shortfall.
- Orphan Drug Status: Soligenix's Dusquetide received orphan drug designation from the European Commission for treating Behçet's Disease, which could provide up to 10 years of market exclusivity if approved, highlighting the company's strategic positioning in the rare disease sector.
- Strategic Options: With approximately $5.9 million in cash, the company plans to evaluate all strategic options moving forward, including potential mergers and acquisitions, while advancing Dusquetide's development to address the challenges posed by the trial failure.
See More
Soligenix Halts HyBryte Clinical Trial Due to Futility
- Trial Results Disappoint: Soligenix announced the pivotal Phase 3 FLASH2 trial of HyBryte™ for cutaneous T-cell lymphoma was recommended to halt due to interim analysis indicating futility, posing significant R&D challenges for the company.
- Cash Position Strained: With approximately $5.9 million in cash, the company must evaluate all strategic options, including merger and acquisition opportunities, to ensure future liquidity and R&D capabilities.
- Efficacy Discrepancies: Despite demonstrating significant efficacy in the first phase trial, HyBryte™ failed to replicate these results in the 18-week FLASH2 trial, indicating uncertainty in the therapy's effectiveness across different patient populations.
- Regulatory Communication Plans: Soligenix intends to communicate with the EMA and FDA regarding the future development of HyBryte™ after further data analysis, reflecting the company's ongoing commitment to exploring the product's potential.
See More
HyBryte™ Shows Promising Results in Treating Cutaneous T-Cell Lymphoma
- Significant Treatment Success: In a 12-week comparative study, 60% of HyBryte™ patients achieved the defined treatment success level (≥50% improvement in mCAILS score), compared to only 20% for Valchlor®, indicating HyBryte™'s potential in treating cutaneous T-cell lymphoma.
- Superior Safety Profile: HyBryte™ was well tolerated in all patients, while 60% of Valchlor® patients experienced treatment-related adverse events, including rashes and allergic reactions, suggesting that HyBryte™ may be a safer treatment option.
- Sustained Efficacy: In the second open-label treatment cycle, 40% of patients receiving 12 weeks of HyBryte™ treatment demonstrated significant treatment response, with results showing a marked improvement compared to the placebo group, indicating that prolonged treatment can enhance patient outcomes.
- Future Research Prospects: The FDA and EMA have mandated a second successful Phase 3 trial for marketing approval, and the follow-up study FLASH2 has successfully achieved its first safety review milestone, which is expected to accelerate the commercialization process for HyBryte™.
See More
Soligenix Reports FY EPS of -$2.14, Beats Estimates
- Fiscal Year Performance: Soligenix reported a FY GAAP EPS of -$2.14, beating market expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Historical Financial Data: Historical data shows that Soligenix's financial performance has fluctuated over the years; although the current EPS remains negative, the better-than-expected result could lay the groundwork for future profitability.
- Market Reaction Analysis: Investors reacted positively to Soligenix's earnings report, which may drive the stock price up in the short term, reflecting market optimism regarding the company's future prospects.
- Quant Rating Attention: Seeking Alpha's Quant Rating on Soligenix highlights market interest in its financial health, prompting investors to closely monitor upcoming financial reports and market developments.
See More
